Hoping to beat the ASX 200? I'd consider buying these 3 ASX shares

Analysts think these shares can outperform the market.

| More on:
Man in an office celebrates at he crosses a finish line before his colleagues.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Historically, the ASX 200 index has generated a return of approximately 10% per annum.

This means that if you want to achieve market-beating returns, you're going to need to achieve a return beyond that.

This is easier said than done. A lot of fund managers struggle to beat the market. It is for this reason that Warren Buffett has often suggested that investors should just buy an index fund and settle for that.

But it isn't impossible. In fact, Buffett has a long track record of delivering market-beating returns for Berkshire Hathaway (NYSE: BRK.B).

So, if I were going to attempt to beat the ASX 200 index, I would follow the Oracle of Omaha's investment strategy.

That strategy is quite simply building a diverse portfolio filled with the highest quality companies you can find with sustainable competitive advantages and fair valuations. This has delivered great results for Buffett and Berkshire Hathaway, and I believe it could do the same for others.

But which ASX shares tick the boxes? Three that have been tipped as buys for investors to consider are listed below:


This biotechnology company's shares have been dragged lower over the last 12 months due partly to a slower-than-expected margin recovery and a disappointing clinical trial result.

Analysts at Morgans think investors should be taking advantage of this. The broker has the ASX share on its best ideas list with an add rating and a $315.40 price target.

This suggests that a potential return of almost 15% is possible over the next 12 months.

ResMed Inc (ASX: RMD)

Another high-quality ASX share that remains down meaningfully on a 12-month basis is sleep treatment company ResMed. This has been driven by concerns that weight loss wonder drugs will negatively impact its growth.

Morgans doesn't believe this will be the case. Its analysts "see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers."

The broker has an add rating and a $32.82 price target on its shares, which implies a potential upside of 14% for investors.

Xero Ltd (ASX: XRO)

Finally, UBS thinks that the recent weakness has created an opportunity for investors to buy this ASX share.

The broker believes that the cloud accounting platform provider can grow its key average revenue per user metric by a compound annual growth rate of 6.5% for the next five years. Though, it concedes that even this may be conservative based on potential price rises and plan upgrades.

UBS has a buy rating and a $141.90 price target on Xero's shares. This suggests a potential upside of 20% for investors from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, ResMed, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Berkshire Hathaway, CSL, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended ResMed and Xero. The Motley Fool Australia has recommended Berkshire Hathaway and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Growth Shares

2 highly rated ASX growth shares to buy before it's too late

Analysts don't want you to miss out on these growing companies.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Growth Shares

5 stellar ASX growth shares to buy for strong returns

Analysts think growth investors should be snapping up these stocks when the market reopens.

Read more »

A group of businesspeople clapping.
Growth Shares

2 of the best growth-focused ASX shares to consider buying in May

Analysts have very good things to say about these growth stocks.

Read more »

Man holding Australian dollar notes, symbolising dividends.
Growth Shares

How ASX growth shares can become top dividend stocks

Are growth stocks passive income power plays in the making?

Read more »

A woman makes the task of vacuuming fun, leaping while she pretends it is an air guitar.

2 top ASX growth shares I'd buy today

I’m bullish about these stocks.

Read more »

A young boy points and smiles as he eats fried chicken.
Growth Shares

The smartest ASX growth shares to buy with $500 right now

I’m bullish about ASX growth stocks at a good price.

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Growth Shares

Aussie investors: 3 ASX shares to buy and hold forever

Analysts think these buy and hold options are top picks right now.

Read more »

Elegant lady with make up wearing jewellery and sitting on a chair.
Growth Shares

Leading broker thinks this top ASX 200 stock's earnings can soar 130% by FY28

This stock could see enormous profit growth in the coming years.

Read more »